

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Sirisanthana, Virat		POSITION TITLE Professor of Pediatrics	
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Mahidol University, Bangkok, Thailand	M.D.	1973	Medicine
University of Illinois Hospital, Chicago, Illinois	Amer. Board of Pediatrics	1977	Pediatrics
University of Illinois Hospital, Chicago, Illinois	Pediatric Infectious Diseases : Research and Clinical Fellow	1979	Infectious Diseases
The Medical Council of Thailand	Pediatric Infectious Diseases Specialist	2004	Pediatric Infectious Diseases

A. Positions and Honors.**Positions**

- 1978 -1979 Instructor, University of Illinois
- 1979 -1981 Instructor, Faculty of Medicine, Chiang Mai University
- 1981 -1984 Assistant Professor, Chiang Mai University
- 1984 -1998 Associate Professor, Faculty of Medicine, Chiang Mai University
- 1998 - present Professor of Pediatrics, Faculty of Medicine, Chiang Mai University
- 2004 - present Co-Investigator, Research Institute for Health Sciences, Chiang Mai University,
110 Intavaroros Road, Chiang Mai 50200 Thailand
- 2006 - present IMPAACT CRS Leader, Research Institute for Health Sciences, Chiang Mai University,
110 Intavaroros Road, Chiang Mai 50200 Thailand

Advisory committee

1. Thai Ministry of Public Health Advisory Committee in Pediatric AIDS.
2. Member of Pediatric Infectious Diseases committee of The Royal College of Pediatricians of Thailand

B. Selected peer-reviewed HIV/AIDS publications (in chronological order).

1. **Sirisanthana V.** Symptomatic human immunodeficiency virus infection in a hill-tribe child. J Pediatr Soc Thai. 1990; 29: 79-89 (in Thai).
2. **Sirisanthana V,** Laoprasert N, Sittiwankul R. Symptomatic vertical HIV infection at Chiang Mai University Hospital. Thai Journal of Pediatrics. 1993;32:95-102 (in Thai)
3. **Sirisanthana V,** Sirisanthana T. Penicillium marneffeii infection in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1993;12:1021-5.
4. **Sirisanthana V,** Angong W. Thalassemic children infected with human immunodeficiency virus at Chiang Mai University Hospital. Thai Journal of Pediatrics 1994;33:107-113 (in Thai).

5. **Sirisanthana V**, Sittiwankul R. Secondary infections in children infected with human immunodeficiency virus. *Thai Journal of Pediatrics* 1994;33:201-211 (in Thai).
6. **Sirisanthana V**, Hemmadhun D. Maternal - infant human immunodeficiency virus transmission in Chiang Mai. *Thai Journal of Pediatrics* 1994;33:193-200 (in Thai).
7. **Sirisanthana V**. Opportunistic infections in HIV-infected children at Chiang Mai University Hospital , Chiang Mai, Thailand. *J Infect Dis Antimicrob Agents (Thai Journal, published in English)* 1995;12:59-62.
8. **Sirisanthana V**. Bacille Calmette-Guerin (BCG) vaccine complications in HIV-infected children. *J Infect Dis Antimicrob Agents (Thai Journal, published in English)* 1995;12:63-67.
9. **Sirisanthana V**, Sirisanthana T. Disseminated *Penicillium marneffei* infection in HIV-infected children *Pediatr Infect Dis J* 1995;14:935-940.
10. **Sirisanthana V**. Demographic and clinical characteristic of symptomatic vertical HIV-infected children at Chiang Mai University Hospital. *J Infect Dis Antimicrob Agents (Thai Journal, published in English)* 1996;13:89-93.
11. **Sirisanthana V**, Likasitwattanakul S, Borisuthipandit T, Thamaprasert K. Nonbronchoscopic bronchoalveolar lavage in HIV-infected children. *Thai Journal of Pediatrics* 1997;36:128-41. (in Thai)
12. **Sirisanthana V**, Apichartpiyakul C, Apichartpiyakul N, Yousukh A. The Prevalence of Cytomegalovirus Infection in Human-Immunodeficiency-Virus-Infected Infants with Pneumonia. *J Infect Dis Antimicrob Agents(Thailand)* 1997;14: 93-6.
13. **Sirisanthana V**, Rangsiyanond P, Louthrenoo O, Sirakamol D, Sirivatanapa P. Mother-to child transmission of human immunodeficiency Virus type 1: report from Chiang Mai study. *Thai Journal of Pediatrics* 1999;38:119-27.
14. Opastirakul S, **Sirisanthana V**. Hypokalemic paralysis in an 8-year-old HIV-infected child. *Thai Journal of Pediatrics* 1998;37:292-5.
15. Ukarapol N, Wongsawasdi L, **Sirisanthana V**. *Penicillium marneffei* mesenteric lymphadenitis in HIV-infected children. *J Med Assoc Thai* 1998;81:637-40
16. Louthrenoo O, **Sirisanthana V**, Rangsiyanond P, Sirakamol D, Sirivatanapa P. Growth and developmental outcome of infants born to HIV infected mothers. *Chiang Mai Med Bull* 1998;37:69-73
17. Ukarapol N, Chartapisak W, Lertprasertsuk N, Wongsawasdi L, Kattipattanapong V, Singhavejsakul J, **Sirisanthana V**. Cytomegalovirus-associated manifestations involving the digestive tract in children with Human Immunodeficiency Virus. *J Pediatr Gastroenterol Nutr* 2002;35:669-673.
18. Puthanakit T, Apichartpiyakul C, **Sirisanthana V**. An in-house HIV DNA PCR assay for early diagnosis of HIV infection in children in Thailand. *J Med ASSOC Thai* 2003; 86:758-765 .
19. Ukarapol N, Lertprasertsuk N, Fuchs GJ, Wongsawasdi L, **Sirisanthana V**. Impact of gastrointestinal endoscopy on HIV-infected children. *Digestive Endoscopy* 2004;16:26-9.
20. Pongprot Y, Sittiwangkul R, Silvilairat S, **Sirisanthana V**. Cardiac manifestations in HIV-infected Thai children. *Ann Trop Paediatr* 2004;24;153-9.
21. Louthrenoo O, Puthanakit T, Wongnum N, **Sirisanthana V**. Early neurodevelopment of infants born to HIV-seropositive mothers. *Chiang Mai Med Bull* 2004;43:1-7.
22. Likasitwattanakul S, Poneprasert B, **Sirisanthana V**. Cryptococcosis in HIV-infected children. *SEA J Trop Med Public Health* 2004;35:935-9.
23. Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, **Sirisanthana V**. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. *Clin Infect Dis* 2005;41:100-7.

24. Puthanakit T, Oberdorfer P, Punjaisee S, Wannarit P, Sirisanthana T, **Sirisanthana V**. Immune reconstitution syndrome from Bacillus Calmette-Gurin after initiating antiretroviral therapy in children with human immunodeficiency virus infection. *Clin Infect Dis* 2005;41:10049-52.
25. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, **Sirisanthana V**. Immune reconstitution syndrome after highly active antiretroviral therapy in HIV-infected Thai children. *Pediatr Inf Dis J* 2006;25:53-8.
26. Oberdorfer P, Puthanakit T, Louthrenoo O, Charmsil C, **Sirisanthana V**, Sirisanthana T. Disclosure of HIV/AIDS diagnosis to HIV-infected children in Thailand. *Journal of Paediatrics and Child Health* 2006;42:283-8.
27. Siriaksorn S, Puthanakit T, Sirisanthana T, **Sirisanthana V**. Prevalence of protective antibody against Hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. *Vaccine* 2006;24:3095-9.
28. Puthanakit T, Oberdorfer P, Ukarapol N, Akarathum N, Punjaisee S, Sirisanthana T, **Sirisanthana V**. Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection. *Pediatr Inf Dis J* 2006;25:645-8.
29. Aурpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, **Sirisanthana V**. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after antiretroviral therapy. *HIV Medicine* 2006;7:467-70.
30. Oberdorfer P, Sennun S, Wongnum N, **Sirisanthana V**. Counseling of HIV-infected pre-adolescents and adolescents at the antiretroviral clinic, Chiang Mai University Hospital. *Thai Journal of Pediatrics* 2006; 45: 95-100.
31. Puthanakit T, Aурpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, **Sirisanthana V**. Hospitalization and mortality of HIV-infected children after receiving highly active antiretroviral therapy. *Clin Infect Dis* 2007;44:599-604.
32. Lao-araya M, Puthanakit T, Aурpibul L, Sirisanthana T, **Sirisanthana V**. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. *Vaccine* 2007;25:5324-9.
33. Aурpibul L, Puthanakit T, Sirisanthana T, **Sirisanthana V**. Response to measles, mumps, rubella re-vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. *Clin Infect Dis* 2007; 45:637-42.
34. Puthanakit T, Aурpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, **Sirisanthana V**. Sustained immunologic and virologic efficacy after 4 years of highly active antiretroviral therapy in human immunodeficiency virus-infected children in Thailand. *Pediatr Inf Dis J* 2007;26:953-6.
35. Aурpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, **Sirisanthana V**. A longitudinal study of lipodystrophy and other metabolic changes in HIV-infected children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *Antiviral Therapy* 2007;12:1247-1254.
36. Puthanakit T, Aурpibul L, Yoksan S, Sirisanthana T, **Sirisanthana V**. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. *Vaccine* 2007;25:8257-61.
37. Oberdorfer P, Louthrenoo O, Puthanakit T, **Sirisanthana V**, Sirisanthana T. Quality of life among HIV-infected children in Thailand. *Journal of the International Association of Physicians in AIDS Care (Chic Ill)* 2008; 7:141-7.
38. Aурpibul L, Puthanakit T, Sirisanthana T, **Sirisanthana V**. Hematologic changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. *HIV Medicine* 2008;9:317-21.

39. Oberdorfer P, Sittiwangkul R, Puthanakit T, Pongprot Y, **Sirisanthana V**. Dilated cardiomyopathy in three HIV-infected children after initiation of antiretroviral therapy. *Pediatrics International* 2008; 50:251-4.
40. Lee B, Aурpibul L, **Sirisanthana V**, Mangklabruks A, Sirisanthana T, Puthanakit T. Low prevalence of insulin resistance among HIV-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. *HIV Med* 2009;10:72-8. (Epub ahead of print *HIV Med* Nov 2008 issue.).
41. Puthanakit T, Aурpibul L, Sirisanthana T, **Sirisanthana V**. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged 2 years or less. *Pediatr Inf Dis J* 2009;28:246-8.
42. Puthanakit T, Kerr SJ, Ananworanich J, Bunupuradah T, Boonrak P, **Sirisanthana V**. Pattern and predictors of immunological recovery in human immunodeficiency virus-infected children receiving non nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. *Pediatr Inf Dis J* 2009;28:488-92.
43. Puthanakit T, Tanpaiboon P, Aурpibul L, Cressey TR, **Sirisanthana V**. Plasma efavirenz concentrations and the association with CYP2B6-516G>T polymorphism in HIV- infected Thai children. *Ativir Ther* 2009;14:315-20.
44. Jittamala P, Puthanakit T, Chaiinseard S, **Sirisanthana V**. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *Pediatr Inf Dis J* 2009 (online 31 Jul 09)
45. Aурpibul L, Puthanakit T, Kanjanavanit S, Sirisanthana T, **Sirisanthana V**. Measles outbreak in an orphanage: HIV-infected children on antiretroviral therapy are still at risk. (Brief report) *Pediatr Inf Dis J* 2009 (inpress).

C. Research Support.

Ongoing Research Support

1) U AI 069399A

Sirisanthana T (PI)

12/01/06 -11/30/07

Fund: NIH/NIAID under The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)

Unit name: Chiang Mai University HIV/AIDS Clinical Trials Unit, Clinical Research Site # 20101

Conducting 3 projects:

- **P1032:** Phase II study of the pharmacokinetics of Nevirapine and the incidence of Nevirapine resistance mutations in HIV-infected women receiving a single intrapartum dose of Nevirapine with the concomitant administration of Zidovudine/ Didanosine or Zidovudine/ Didanosine/Lopinavir/ Ritonavir
Role: Site-Leader
- **P1054:** Assessment of Safety and Toxicity among Infants Born to HIV-1-infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World.
Role: Site-Leader
- **P1069:** A phase I/II comparative pharmacokinetic study of the fixed-dose combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC) and Nevirapine (NVP) as GPO-VIR[®] Z30 pediatric tablets versus the individual liquid formulations in HIV-infected children ≥ 5 months to < 13 years of age in Thailand
Role: Site-Leader and Principal Investigator
- **P1077HS:** HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)
Role: Principal Investigator

- 2) **Puthanakit T (PI)** 8/01/03-7/31/08
Fund: Thai Government Pharmaceutical organization
Title: Clinical, virological and immunological responses of HIV-infected children to highly active antiretroviral treatment (5 years study)
Goal: To assess the clinical, virological, immunological responses and the adverse drug reactions to NNRTI-based HAART in HIV-infected children.
Role: Co-Investigator
- 3) **A4001031 Sirisanthana T (PI)** 3/02/09-3/02/14
Fund: Pfizer (Thailand) Limited
Title: An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic and 48-Week Safety and Efficacy Trial of Maraviroc in Combination with Optimized Background Therapy for the Treatment of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2-18 Years of Age (5 years study)
Goal: 1. To determine the pharmacokinetics (PK) profile and dosing schedule of MVC in treatment experienced HIV-infected children and adolescents on different background therapies
2. To determine the safety and tolerability of MVC in HIV-infected children and adolescents
Role: Principal Investigator

Complete Research Support

- 1) **U AI 069399A Sirisanthana T (PI)** 12/01/06 -11/30/07
Fund: NIH/NIAID under The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
Unit name: Chiang Mai University HIV/AIDS Clinical Trials Unit, Clinical Research Site # 20101
 - **P1056:** A phase I/II comparative pharmacokinetic study of the fixed-dose combination (FDC) of stavudine(d4T), lamivudine (3TC), and nevirapine (NVP), as GPO-vir pediatric chewable tablets versus the individual liquid formulations in HIV-infected children \geq 6 months to < 13 years of age in Thailand
Role: Site-Leader
- 2) **R01 TW006187 Puthanakit T (PI)** 9/24/02-6/30/07
Fund: FIC/NHLBI/OBSSR
Title: Effect of the HIV epidemic on children in Thailand
Goal: To characterize the natural history of HIV-infected children in Thailand and to characterized psychosocial problems of school-aged children in Thailand
Role: Co-Investigator
- 3) **U01AI41089 Puthanakit T (PI)** 2/01/05-1/31/06
Fund: NIH/NIAID
Title: Pediatric AIDS Clinical Trials Group Network (PACTG), International site# 20101
Goal: Establishment of a functioning Pediatric AIDS clinical trials unit.
Role: Co-Investigator
- 4) **33/2548 Puthanakit T (PI)** 1/01/05-12/31/05
Fund: Thailand Research Fund of the Royal Thai Government and Faculty of Medicine Chiang Mai University research fund
Title: Immune function after Highly active antiretroviral therapy (HAART)
Goal: To determine the prevalence of protective antibody levels for Hepatitis B, Japanese encephalitis, Measles, Mumps, Rubella, Diphtheria, Tetanus and Pertussis in HIV-infected children with immune recovery after Highly active antiretroviral therapy (HAART)
Role: Co-Investigator

- 5) **Oberdorfer P (PI)** 1/11/04-1/05/05
Fund: The Thailand Research Fund - Senior Research Scholar – Thira Sirisanthana
Title: Health-related Quality of Life among HIV-infected Children
Goal: To assess QOL among HIV-infected children receiving HAART
Role: Co-investigator
- 6) **Oberdorfer P (PI)** 1/07/04-1/07/06
Fund: The Ministry of Education and The Thailand Research Fund of the Royal Thai Government
Title: Disclosure of HIV/AIDS to HIV-infected children in Thailand
Goal: 1. To determine disclosure patterns of HIV/AIDS status to HIV-infected children.
2. To develop disclosure guidelines for Thai children
Role: Co-investigator